ArticleJournal of medicinal chemistry2021

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.

Ryan R Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.